Biopsy-Proven Myeloperoxidase (MPO)-ANCA Glomerulonephritis Relapse Despite Peripheral CD19+ B-Cell Depletion After Rituximab (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO0790; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "She was treated with pulse steroids, rituximab, and maintained on avacopan and low-dose steroids...She was treated with pulse steroids, cyclophosphamide and was given her maintenance dose of rituximab...Possible mechanisms include persistent CD20-negative plasma cell–mediated ANCA production, incomplete depletion of tissue-resident B cells, and possible T cell–mediated mechanisms of injury. In patients with worsening kidney function and active urine sediment, repeat kidney biopsy remains essential even when peripheral CD19 B-cells are undetectable."
Biopsy • Acute Kidney Injury • ANCA Vasculitis • Cardiovascular • Diabetes • Fibrosis • Glomerulonephritis • Hypertension • Immunology • Inflammatory Arthritis • Lupus Nephritis • Metabolic Disorders • Nephrology • Renal Disease • Rheumatoid Arthritis • Type 2 Diabetes Mellitus • Vasculitis • CD20 • MPO
|
|
Ahmed Salik; Vamshi K. Garlapaty; Jamal Abu-Khaled; Ping L. Zhang
|